Compare Moderna, Inc. (MRNA) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Moderna, Inc. trades at $219.07 (market cap $78.65B), while Vanguard Total Stock Market Index Fund ETF trades at $381.72 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 29.2× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Vanguard Total Stock Market Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| MRNA | VTI | |
|---|---|---|
Market Cap | $78.65B | $2.30T |
Volume | 37,373,437 | 2,982,924 |
Sector | Health | — |
52-Week High | $203.46 | $384.30 |
52-Week Low | $22.36 | $311.68 |
Typical Hold Time | 59 Days | 131 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
VTI trades at $380.52, down slightly by 0.13% with a bullish technical signal from moving averages. The ETF maintains broad U.S. equity exposure across 3,500+ stocks, though concentration in top holdings remains significant. Recent news highlights long-term growth potential with $500 monthly investments since 2001 growing to approximately $876,000 according to Motley Fool (2026-10-01).
VTI offers diversified U.S. market access with low costs, suitable for long-term investors. Risks include market concentration in top holdings and broader economic sensitivity. Analyst sentiment remains positive for buy-and-hold strategies, though recent articles question the value added by small/mid-cap exposure versus S&P 500-focused alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
